Radiation protection aspects for alpha therapies.

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Therapy
• Radiation Safety

Background:

• Alpha emitting radiotherapeutics are gaining prominence in clinical trials and treatment.
• Existing literature on radiation safety for alpha emitters is scarce, primarily focusing on 223Ra.
• Newer alpha emitters possess diverse decay chains and properties requiring specific safety considerations.

Purpose of the Study:

• To highlight the growing importance of alpha emitting radiotherapeutics.
• To underscore the limitations in current radiation safety literature for these agents.
• To emphasize the need for comprehensive risk assessments and safety protocols.

Main Methods:

• Review of existing literature on alpha emitting radionuclides.
• Analysis of potential occupational and public exposure risks.
• Identification of critical safety aspects including contamination, ingestion, and waste management.

Main Results:

• Occupational and external public exposure from alpha emitters are generally low but require vigilance.
• Skin contamination, inhalation, and ingestion are key routes of exposure to manage.
• Long-lived progeny and impurities necessitate careful examination of decay chains and manufacturing processes.

Conclusions:

• Increased use of alpha emitters demands expanded radiation safety literature, especially for novel agents.
• Thorough risk assessments covering preparation, administration, and incident management are imperative.
• Robust safety protocols are essential to mitigate risks associated with diverse alpha emitting radiotherapeutics.